• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Aptose Biosciences Inc. (Amendment)

    2/14/24 4:51:40 PM ET
    $APTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $APTO alert in real time by email
    SC 13G/A 1 tm243309d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

     SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

    Aptose Biosciences Inc.

    (Name of Issuer)

     

    Common Shares, no par value

    (Title of Class of Securities)

     

    03835T200 

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

    CUSIP NO. 03835T200 Page 2 of 7

     

    CUSIP No.  03835T200
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 120,132
    (7) Sole dispositive power 0
    (8) Shared dispositive power 120,132
    (9) Aggregate amount beneficially owned by each reporting person 120,132
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 1.5%
    (12) Type of reporting person (see instructions) IA

     

     

     

     

    CUSIP NO. 03835T200 Page 3 of 7

     

    CUSIP No.  03835T200
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 120,132
    (7) Sole dispositive power 0
    (8) Shared dispositive power 120,132
    (9) Aggregate amount beneficially owned by each reporting person 120,132
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 1.5%
    (12) Type of reporting person (see instructions) HC

     

     

     

     

    CUSIP NO. 03835T200 Page 4 of 7

     

    CUSIP No.  03835T200
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 120,132
    (7) Sole dispositive power 0
    (8) Shared dispositive power 120,132
    (9) Aggregate amount beneficially owned by each reporting person 120,132
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 1.5%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      Aptose Biosciences Inc. (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
      251 CONSUMERS ROAD SUITE 1105, TORONTO, A6 M2J 4R3
       
    Item 2(a). Name of Person Filing
       
     

    Nantahala Capital Management, LLC (“Nantahala”)

    Wilmot B. Harkey

    Daniel Mack (together the “Reporting Persons”)

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    130 Main St. 2nd Floor

    New Canaan, CT 06840

     

    Item 2(c). Citizenship:
       
     

    Nantahala is a Massachusetts limited liability company.

    Each of Messrs. Harkey and Mack is a citizen of the United States of America.

       
    Item 2(d).

    Title of Class of Securities:

     

     

    Common Shares, no par value (the “Shares”).

     

     

     

     

    CUSIP NO. 03835T200 Page 5 of 7

     

    Item 2(e).

    CUSIP Number:
     

     

    03835T200

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4.

     

    Ownership:

       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2023, Nantahala may be deemed to be the beneficial owner of 120,132 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2023, each of the Reporting Persons may be deemed to be the beneficial owner of 1.5% of the total number of Shares outstanding.

     

     

     

     

    CUSIP NO. 03835T200 Page 6 of 7

     

    Item 4(c). Number of shares as to which such person has:
       
     

    Nantahala Capital Management, LLC

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 120,132
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 120,132
     

     

    Each of Messrs. Harkey and Mack

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 120,132
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 120,132
           
    Item 5. Ownership of Five Percent or Less of a Class:
       
      The Reporting Persons have ceased to be beneficial owners of more than five percent of the Common Stock.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      This Item 6 is not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E). See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:
       

     

    By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP NO. 03835T200 Page 7 of 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 14, 2024 NANTAHALA CAPITAL MANAGEMENT, LLC
         
      By: /s/ Taki Vasilakis
      Taki Vasilakis
      Chief Compliance Officer
         
      /s/ Wilmot B. Harkey
      Wilmot B. Harkey
         
      /s/ Daniel Mack
      Daniel Mack

     

     

     

    Get the next $APTO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $APTO

    DatePrice TargetRatingAnalyst
    12/21/2021$14.00 → $12.00Buy
    HC Wainwright & Co.
    11/12/2021$9.00 → $14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $APTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chair, President & CEO Rice William G. bought $20,000 worth of shares (100,000 units at $0.20), increasing direct ownership by 19% to 613,252 units (SEC Form 4)

      4 - Aptose Biosciences Inc. (0000882361) (Issuer)

      11/26/24 6:56:32 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Seizinger Bernd R. bought $53,380 worth of shares (17,000 units at $3.14)

      4 - Aptose Biosciences Inc. (0000882361) (Issuer)

      9/25/23 5:03:39 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    SEC Filings

    See more
    • Aptose Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Aptose Biosciences Inc. (0000882361) (Filer)

      4/23/25 5:00:09 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRER14A filed by Aptose Biosciences Inc.

      PRER14A - Aptose Biosciences Inc. (0000882361) (Filer)

      4/23/25 6:04:58 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Aptose Biosciences Inc.

      8-K - Aptose Biosciences Inc. (0000882361) (Filer)

      4/21/25 5:28:56 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Hanmi Pharmaceutical Co., Ltd. claimed ownership of 508,710 shares (SEC Form 3)

      3 - Aptose Biosciences Inc. (0000882361) (Issuer)

      3/20/25 8:54:45 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chair, President & CEO Rice William G. bought $20,000 worth of shares (100,000 units at $0.20), increasing direct ownership by 19% to 613,252 units (SEC Form 4)

      4 - Aptose Biosciences Inc. (0000882361) (Issuer)

      11/26/24 6:56:32 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Ledru Philippe

      4 - Aptose Biosciences Inc. (0000882361) (Issuer)

      5/10/24 11:35:32 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

      Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients SAN DIEGO and TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS, OTC:APTOF), a clinical-stage precision oncology company, today reported updated and new data from Aptose's Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) patients dosed with a 40 mg or 80 mg dose of tuspe

      5/5/25 7:00:00 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aptose Announces Auditor Not Standing for Re-Appointment

      SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the "KPMG"), informed the Company that it will not stand for re-appointment for the Company's 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two fiscal quarters of 2025. The Company

      4/23/25 5:00:00 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

      SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto, May 5-6, 2025. Dr. William G. Rice, Chairman, President and CEO of Aptose, will present on May 5, 2025 and will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with Aptose please contact your conference repre

      4/23/25 7:30:00 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Aptose Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Aptose Biosciences with a rating of Buy and set a new price target of $12.00 from $14.00 previously

      12/21/21 5:27:22 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Aptose Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Aptose Biosciences with a rating of Buy and set a new price target of $14.00 from $9.00 previously

      11/12/21 6:08:40 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Aptose Biosciences with a new price target

      Oppenheimer reiterated coverage of Aptose Biosciences with a rating of Outperform and set a new price target of $9.00 from $8.00 previously

      3/24/21 6:57:14 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    Leadership Updates

    Live Leadership Updates

    See more
    • NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer

      NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer Greg brings over 25 years of public and private company leadership experience Philadelphia, PA, August 1, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Greg Chow as Chief Financial and Business Officer (CFBO), effective immediately. Greg is an experienced executive with over 25 years of corporate finance, capital markets, investment banking, financial accounting, drug development operations, and business development experience. Over th

      8/1/24 7:00:00 AM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aptose Announces Results from Annual and Special Meeting of Shareholders

      SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company's annual and special meeting of shareholders held today, June 18, 2024 (the "Meeting"). A total of 8,101,527 common shares of the Company, representing 49.67% of the common shares of the Company entitled to be voted, were represented by shareholders present or represented by proxy at the Meeting. The Company is pleased to announce that all of the nominees listed in the proxy

      6/18/24 5:30:00 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

      SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer. With a healthcare tenure of more than 25 years, Mr. Payne has held several CFO and senior management positions at biotech companies in addition to finance and accounting roles, and has overseen legal, corporate development and licensing functions. During his career, he has execu

      11/30/23 4:59:54 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    Financials

    Live finance-specific insights

    See more
    • Aptose Reports Results for the First Quarter 2024

      TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML Conference Call and Webcast at 5:00 pm ET Today   SAN DIEGO and TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the first quarter ended March 31, 2024. The Company will p

      5/14/24 4:01:00 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

      SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 14, 2024, after the close of the market, and provide a corporate update. In addition, Rafael Bejar, MD, PhD, the Company's Chief Medical Officer and resident Key Opinion Leader, will review a selection of slides and discuss the clinical strategy for advancing the Company's lead asset tuspetinib (TUS) in a TUS+VEN+HMA triplet drug combination for the frontline treatmen

      5/6/24 4:30:00 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

      SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update. Conference Call & Webcast:  Date:Tuesday, March 26, 2024Time:5:00 PM ETAudio Webcast Only:linkQ&A Participant Registration Link*:link(https://register.vevent.com/register/BIe69f08fc83634a6aa38bf7081d82c6a2)   *Analysts interested in participating in the question-and-answer sess

      3/18/24 4:30:00 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $APTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aptose Biosciences Inc.

      SC 13G - Aptose Biosciences Inc. (0000882361) (Subject)

      11/14/24 3:22:02 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Aptose Biosciences Inc. (Amendment)

      SC 13D/A - Aptose Biosciences Inc. (0000882361) (Subject)

      4/26/24 12:54:08 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Aptose Biosciences Inc. (Amendment)

      SC 13G/A - Aptose Biosciences Inc. (0000882361) (Subject)

      2/14/24 4:51:40 PM ET
      $APTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care